Effect of Zilongjin Tablets on survival time of patients with advanced non-small cell lung cancer
Objetive To investigate the effect of Zilongjin Tablets on the survival time of patients with advanced non-small cell lung cancer. Methods A prospective,observational real-world study was used. The research database was composed of data proactively collected for the purpose of this study,medical and health data from Beijing Hospital of Traditional Chinese Medicine. The data of patients in the Phase ⅢB～Ⅳ clinical stage were extracted. Whether or not Taking Zilongjin tablets was considered as an exposure factor. The information including patients' demography, lung cancer diagnosis, treatment, and administration of ZilongjinTtablets were extracted and Kaplan-Meier method was used for univariate analysis,and COX model method was used for multivariate survival analysis. Results A total of 301 cases were included, including 99 exposed queues and 202 unexposed queues. The proportion of surgical treatment in exposed group was higher than that in non-exposed group (P<0.05). The estimated mean survival time in the exposed cohort was 1085.990 d [95％ CI (964.694,1207.286)], higher than that in the non-exposed cohort 840.074 d[95％ CI(748.942,931.207)], the difference was statistically significant (P=0.002). Univariate analysis showed that sex, age, pathological type, TNM clinical stage, surgical treatment and exposure to Zi Long gold tablets were related to survival time (P≤0.1). COX survival analysis showed that older age, squamous cell carcinoma and late clinical stage were independent risk factors for terminal events, while female, surgery, chemotherapy, targeted therapy and exposure to Zilongjin Tablets were independent protective factors, among which there were statistically significant differences between clinical stage, surgery and exposure to Zilongjin Tablets (P<0.05). Conclusion Based on the current data and analysis methods,the treatment with Zilongjin Tablets has a relatively clear protective effect on the survival in patients with advanced non-small cell lung cancer.
Advanced non-small cell lung cancerreal world dataZilongjin Tabletspost-marketing evaluation of Chinese patent medicine
万方数据
维普
